Immuron PR Confirms Co. Recently Executed SARS-CoV-2 Research Services Agreement With Monash University To evaluate IMM-124E
6:52 am ET December 15, 2020 (Benzinga) Print
Immuron's Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.
A
Immuron's Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.
A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron's marketed products (IMM-124E).
MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and international research collaborators to advance this work and assist in the further characterization of the neutralization activity of SARS-CoV-2 observed with Immuron's commercial hyper-immune colostrum used to manufacture the company's flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn®.
The company has recently executed a new Research Agreement with Monash University to develop new assays to evaluate the efficacy of IMM-124E, the active pharmaceutical ingredient used to manufacture Travelan® and Protectyn® to further our understanding of the inhibitory substance/s in our commercial products.
The research team will be led by Dr Melanie Hutton and Professor Dena Lyras, Deputy Director, Biomedicine Discovery Institute and Deputy Head, Department of Microbiology who will utilize two new recombinant reagents, the SARS-CoV-2 Spike protein, a receptor binding domain protein as well as an antibody positive human serum sample obtained from Melbourne's Peter Doherty Institute for Infection and Immunity.
"We have been very fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity," said Professor Lyras. "These reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E. Furthermore, specific immune components will be purified from IMM-124E and will be used to evaluate their ability to inhibit the binding of an antibody positive human serum sample to specific COVID-19 proteins, such as the spike protein which is crucial for cell entry," said Dr Hutton.
This release has been authorised by the directors of Immuron Limited.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Recent IMRN News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/22/2024 04:15:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:14:35 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/15/2024 12:00:09 PM
- Immuron announces record Travelan® sales globally, Australia and USA • GlobeNewswire Inc. • 07/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/09/2024 10:09:39 AM
- Immuron requests pre-IND meeting for IMM-529 with FDA filing • GlobeNewswire Inc. • 07/02/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 10:12:05 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 12:00:38 PM
- Immuron Board Changes • GlobeNewswire Inc. • 05/31/2024 10:00:00 AM
- Immuron CEO Steven Lydeamore to present at Peak Sky High • GlobeNewswire Inc. • 05/31/2024 10:00:00 AM
- Immuron Director Resignation • GlobeNewswire Inc. • 05/03/2024 10:00:00 AM
- Immuron to host Live Virtual Event • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Immuron Travelan® sales continued strong growth • GlobeNewswire Inc. • 04/10/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:00:20 PM
- Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US • GlobeNewswire Inc. • 03/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 01:08:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 01:00:38 PM
- Immuron Presentation Australian Biologics Festival 2024 • GlobeNewswire Inc. • 02/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 01:00:12 PM
- Immuron achieves record Travelan® sales • GlobeNewswire Inc. • 02/13/2024 11:00:00 AM
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 02/08/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 01:00:11 PM
- Immuron achieves record half yearly Travelan® sales • GlobeNewswire Inc. • 01/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 12:21:42 PM
- Immuron Clinical Trials Update • GlobeNewswire Inc. • 12/22/2023 11:00:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM